Zura's IL-17/BAFF Bispecific Misses in Hidradenitis Suppurativa
- Zura Bio said both doses of tibulizumab, a bispecific blocking IL-17 and BAFF, failed to beat placebo on the primary endpoint in the Phase 2 TibuSHIELD study in hidradenitis suppurativa.
- Key secondary endpoints also missed, and the company is ending development in this indication; the stock fell sharply.
- Work continues in systemic sclerosis, with a polymyalgia rheumatica study planned.
💡 Points Based on public reports
The treated arms improved a lot, but so did placebo, which is the familiar HS trap that has sunk other mid-stage programs. The readout also arrived earlier than the company's own guidance. The real exposure is the rest of the pipeline: IL-17 plus BAFF now has to prove its dual mechanism in systemic sclerosis, where a cash-limited company has no second shot.
Zura reports Phase 2 flop in painful skin disorder, stock nosedives ↗